<DOC>
	<DOCNO>NCT02106793</DOCNO>
	<brief_summary>Primary objective - To compare incidence postoperative nasal synerchia Mitomicin C placebo patient 6 month endoscopic sinus surgery - To validate Thai version disease-specific quality life tool SNOT-22 Secondary objectives - To compare clinical sign symptom CRS patient receive Mitomicin C receive placebo - To compare disease-specific quality life patient receive Mitomicin C receive placebo - To compare side effect Mitomicin C versus placebo</brief_summary>
	<brief_title>Mitomicin C Prevention Postoperative Endoscopic Sinus Surgery Synechia QOL Chronic Rhinosinusitis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>All Thai adult ( 18 year old ) patient undergo bilateral endoscopic sinus surgery CRS Patients must follow disease condition Cystic fibrosis base positive sweat test DNA test Gross immunodeficiency ( congenital acquire ) Congenital mucociliary problem ( eg . Primary ciliary dyskinesia ) Altered immune function patient systemic vasculitis , systemic lupus erythematosus , end stage renal disease , cirrhosis , currently take immunosuppressant granulomatous disease Severe comorbidity life expectancy le 1 year , advance stage malignancy patient , severe infection Patients willing participate provide write informed consent ( None )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Rhinosinusitis</keyword>
	<keyword>Mitomicin C</keyword>
	<keyword>Postoperative nasal synerchia</keyword>
</DOC>